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http://dx.doi.org/10.1016/j.jmii.2012Background: Pneumocystis jiroveci pneumonia (PJP) is a life-threatening disease in immuno-
compromised patients. Improved knowledge about the varied characteristics and management
in different populations may guide treatment.
Methods: We evaluated the clinical characteristics, management, and outcomes of patients
with PJP diagnosed by nested polymerase chain reaction at a medical center in southern
Taiwan from 2008 to 2011. The risk factors of mortality among non-human immunodeficiency
virus (HIV)-infected patients were analyzed.
Results: During the study period, there were 43 cases of PJP, and the common underlying
diseases were HIV infection (23 patients, median CD4 count: 19/ml) and malignancy. The
HIV-infected patients had a younger age (36.9  13.7 vs. 50.2  16.2 years, pZ 0.006), a lower
body mass index (19.9  2.3 vs. 22.0  3.7 kg/m2, pZ 0.035), a longer duration of symptoms
before admission (24  29 vs. 7  15 days, p Z 0.035), and a lower pneumonia severity index
(56  25 vs. 99  35, p < 0.001) than non-HIV-infected patients. A delay between admission
and starting antimicrobial therapy for PJP (10  10 days vs. 1  3 days, pZ 0.004) and a high
crude mortality (12/20, 60% vs. 2/23, 9%, pZ 0.001) were noted in non-HIV-infected patients.
In the univariate analysis, the risk factors for mortality were a low lymphocyte count (p < 0.05)
and shock during hospitalization (p Z 0.004).
Conclusion: A delay in the initiation of antimicrobial therapy for PJP and severe pneu-
monia were more common in the non-HIV-infected patients and were most likely relatedof Internal Medicine, National Cheng Kung University Hospital, Number 138, Sheng Li Road, Tainan
il.com (W.-C. Ko).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
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Pneumonia in immunocompromised patients 43to the poor prognosis. The utilization of sensitive diagnostic tools to facilitate early diag-
nosis and treatment may improve the clinical outcomes of non-HIV-infected patients with
PJP.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Pneumocystis jiroveci pneumonia (PJP) is a severe and
potentially fatal opportunistic infection in immunosup-
pressed patients.1,2 Several published studies had revealed
that that clinical characteristics of PJP vary between
patients with and without human immunodeficiency virus
(HIV) infection.2e4 It is difficult to diagnose PJP due to the
lack of a reliable culture system for P. jiroveci. However,
the development of a polymerase chain reaction (PCR)
technique has allowed substantial progress in diagnosis and
enhanced the sensitivity and specificity of P. jiroveci
detection.5
The incidence of PJP in HIV-infected patients declined
21.5% per year between 1996 and 1998.6 This decline has
been attributed to the availability of highly active anti-
retroviral therapy.7 However, an increasing number of
sporadic cases of PJP among the individuals without HIV
infection has been noted in recent years.4,8 In addition, the
number of susceptible people is increasing because PJP
may develop after the clinical application of monoclonal
antibody therapy for the treatment of autoimmune
diseases.9,10 In addition, several clusters of P. jiroveci
infection among kidney transplant recipients have been
reported.11,12 Most importantly, the mortality rate of PJP
among the patients without HIV infection was as high as
59%, generally worse than that in the patients with
acquired immunodeficiency syndrome.4
Thus, we intended to analyze the clinical characteris-
tics, treatment, and outcomes of non-HIV-infected patients
with PJP to identify the factors associated with mortality.
HIV-infected patients with PJP were used as the control
population.Materials and methods
From October 2008 to September 2011, the patients
admitted to the National Cheng Kung University Hospital,
a medical center in southern Taiwan, who were diagnosed
with PJP were included in this study. Four inclusion criteria
had to be met by each patient included in this study: (1) the
presence of relevant pulmonary symptoms, i.e., cough or
dyspnea, (2) pulmonary infiltration observed by chest
radiography or computed tomography, (3) detection of
P. jiroveci DNA fragments in the samples of sputum, bron-
choalveolar lavage fluid, or lung tissue by nested PCR, as
described in published reports,2,3,13 and (4) the receipt of
antimicrobial therapy for PJP during hospitalization.
The clinical samples used for nested PCR can be
expectorated or induced sputum, bronchoalveolar lavage
fluid, or lung tissue. DNA extraction and DNA amplification
were performed as previously described.14 The first round
of PCR was performed with the oligonucleotide primerspAZ102-H and pAZ102-E, which were designed to amplify
the gene encoding the mitochondrial large subunit rRNA
of P. jiroveci. The second round of PCR was performed
with two sets of primer pairs, each of which had an EcoRI
restriction endonuclease site incorporated at the 50
end: pAZ102-X/R1 (50-GGGAATTCGTGAAATACAAATCGG-
ACTAGG-30) with pAZ102-Y/R1 (50-GGGAATTCTCACTT
AATATTAATTGGGGAGC-30) and pAZ102-X/R1 with pAZ102-
L1R/R1 (50-GGGAATTCTCTCGACTCCTCACCT TAT-30).
Clinically, hypoxemia was defined as either an oxyhe-
moglobin saturation of less than 95% measured by pulse
oximetry under room air or the need for oxygen. Hospital-
onset PJP referred to the patients who developed relevant
symptoms more than 48 hours after admission. In this study,
cardiovascular disease refers to stroke and coronary artery
disease. Prior pulmonary diseases were defined as a history
of physician-diagnosed nonmalignant lung disease, such as
pulmonary tuberculosis, chronic bronchitis, emphysema,
interstitial lung disease, or autoimmune disease with lung
involvement.
When calculating the dose of co-trimoxazole (or
trimethoprim/sulfamethoxazole) for the treatment of PJP,
we excluded the patients with impaired renal function
because the dosage of co-trimoxazole should be lower for
such patients; therefore, averaging the doses used in
patients with and without impaired renal function will
result in an underestimate of the dosage. The clinical data
retrieved from the medical records included demographic
characteristics, comorbid conditions, clinical features at
presentation, laboratory test results, radiologic images, use
of antimicrobial therapy for PJP, and clinical outcome. The
pneumonia severity index was used to grade the severity of
pneumonia.15
Statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS) for Windows (version
17.0; SPSS Inc., Chicago, IL, USA). Continuous variables
were analyzed using the independent t test, and categor-
ical variables were compared by the Chi-square or Fisher’s
exact test. A p value of <0.05 was considered statistically
significant.Results
Demographic data and underlying disease
Forty-three patients were diagnosed as having PJP during
the study period. There were 23 HIV-infected patients and
20 patients who were immunocompromised due to medi-
cations or illness other than HIV infection (Table 1). Most
clinical respiratory samples with positive results in the
nested PCR were expectorated or induced sputum (22/23
for the HIV-infected patients and 15/20 for the non-HIV-
infected patients). P. jiroveci DNA fragments were also
Table 1 Characteristics and outcomes of patients with PJP with and without HIV infection
Variables Patients, N (%) p
HIV, n Z 23 Non-HIV, n Z 20
Age, y (mean  SD) 36.9  13.7 50.2  16.2 0.006
Male 23 (100) 9 (45) <0.001
Body mass index, kg/m2 (mean  SD) 19.9  2.3 22.0  3.7 0.04
Underlying diseases
Hematologic malignancy 0 5 (25) 0.02
Solid organ malignancy 0 3 (15) 0.09
Autoimmune disease 0 8 (40) 0.001
Recipient of a kidney transplant 0 2 (10) 0.21
Chronic kidney disease 0 3 (15) 0.09
Cardiovascular disease 2 (9) 3 (15) 0.65
Prior pulmonary diseases 3 (13) 4 (20) 0.69
Prior PJP chemoprophylaxis 1 (4) 0 1.00
Symptom onset before admission, d (mean  SD)a 24  29 7  15 0.04
Severity markers at presentation
Hypoxemiab 14 (61) 14 (70) 0.53
Pneumonia severity index (mean  SD) 56  25 99  35 <0.001
Hypotension 1 (4) 4 (20) 0.17
Concurrent respiratory tract infection 8 (35) 2 (10) 0.08
Laboratory findings (mean  SD)
White blood cell count, cells/ml 6839  2678 9070  4934 0.07
Lymphocytes, cells/ml 782  609 915  903 0.57
Hemoglobin, g/dl 10.9  1.9 11.2  2.3 0.60
Platelets, cells  103/ml 261  109 205  129 0.13
Treatment of PJP
Initiation after admission, d (mean  SD)a 1  3 10  10 0.004
Dose of co-trimoxazole, mg/kg/d (mean  SD)c 14.3  2.2 13.5  3.6 0.44
Adjuvant steroid use 16 (70) 20 (100) 0.01
Outcome
Pneumothorax 1 (4) 2 (10) 0.59
Shock during hospitalization 2 (9) 13 (65) <0.001
Admission to ICU 2 (9) 18 (90) <0.001
Total hospital stay, d (mean  SD)a 20  11 31  13 0.007
ICU stay, d (mean  SD) 18  3 16  3 0.87
Respiratory failure 2 (9) 18 (90) <0.001
Crude mortality 2 (9) 12 (60) <0.001
a Four non-HIV-infected patients with hospital-onset PJP were excluded.
b Oxyhemoglobin saturation <95% (pulse oximetry) in room air or the need for oxygen.
c A total of five patients, including those with impaired renal function, a history of co-trimoxazole allergy, and those whose doses were
changed due to adverse events, were excluded for the dose evaluation. The dose refers to that of trimethoprim.
Note: Prior pulmonary disease denotes a history of physician-diagnosed nonmalignant pulmonary disorder; cardiovascular disease:
coronary artery disease or stroke.
HIV Z human immunodeficiency virus; ICU Z intensive care unit; PJP Z Pneumocystis jiroveci pneumonia; SD Z standard deviation.
44 M.-C. Li et al.detected in bronchoalveolar lavage fluid (one HIV-infected
patient and three non-HIV-infected patients) and lung
tissue (two non-HIV-infected patients).Clinical characteristics and laboratory findings
Among the HIV-infected patients, the CD4 counts were
often less than 100/ml, and the majority of these patients
(91%) were naı¨ve to antiretroviral therapy at the time of
presentation. Male sex (23, 100%), a younger age
(36.9  13.7 vs. 50.2  16.2 years, pZ 0.006), a lower body
mass index (19.9  2.3 vs. 22.0  3.7 kg/m2, p Z 0.035),
and a longer duration of prodromal symptoms (24  29 vs.7  15 days; pZ 0.035) were more common among the HIV-
infected patients than among the non-HIV-infected patients
(Table 1). However, the severity of illness at presentation,
represented by the pneumonia severity index, was lower in
the HIV-infected patients (mean 56 vs. 99, p < 0.001),
although the numbers of patients presenting with hypox-
emia or hypotension did not differ between the two groups
(Table 1). The white blood cell, lymphocyte, and platelet
counts and the hemoglobin levels were similar in the two
groups. Regarding concurrent respiratory tract infections,
in the HIV group, there were three cases of nontuberculous
Mycobacterium infection, two cases of pulmonary crypto-
coccosis, one case of cytomegalovirus infection, one case
of influenza virus A infection, and one case of bacterial
Pneumonia in immunocompromised patients 45infection. In the non-HIV-infected group, one patient had
a concurrent cytomegalovirus infection and another was
infected with influenza virus A.
Treatment and outcomes
There were four cases of hospital-onset PJP in the non-HIV-
infected group and no such cases in the HIV-infected group.
The delay in the initialization of specific antimicrobial
therapy for PJP, i.e., co-trimoxazole, after admission was
longer in the non-HIV-infected group (10 vs. 1 days,
pZ 0.004), after excluding the four patients with hospital-
onset PJP (Table 1). Among the 43 patients with PJP, most
(33, 73%) received concurrent b-lactam therapy. Further-
more, there were 14 (33%) patients who received a macro-
lide, 11 (26%) who received fluoroquinolone, four (9%) who
received ganciclovir, and three (7%) who received an anti-
fungal agent when they were treated for PJP.
The average dosages of co-trimoxazole for PJP were
similar between the two groups (based on trimethoprim:
14.3 mg/kg/day in HIV-infected patients vs. 13.5 mg/kg/
day in non-HIV-infected patients, p Z 0.4). Due to the
presence of a history of allergy (one case) or to adverse
reactions (18 cases) related to co-trimoxazole, there were
10 (43%), and nine (45%) patients that received a combina-
tion of primaquine and clindamycin in the HIV-infected and
non-HIV-infected groups, respectively (p Z 0.9). The
intervals between the initiation of co-trimoxazole and the
switch to primaquine plus clindamycin were 11.7  3.8 and
11.1  7.4 days in the HIV and non-HIV-infected groups,
respectively. With regard to the reasons for the switch to
primaquine use, two non-HIV-infected patients had
presumed renal toxicity, six (five HIV-infected and one non-
HIV-infected) had skin rashes, and eight (three HIV-infected
and five non-HIV-infected) had hematologic toxicity. In the
HIV-infected group, the hospital stay was shorter (20 vs. 31
days, p Z 0.007), and there were fewer admissions to an
intensive care unit (ICU) due to respiratory failure (2/23, 9%
vs. 18/20, 90%; p < 0.010). There were more cases of shock
during hospitalization (13/20, 65% vs. 2/23, 9%; p < 0.001)
and more deaths in the non-HIV-infected group (12/20, 60%
vs. 2/20, 9%; p < 0.001).
Because there was a lower mortality rate in the HIV-
infected group, further analysis to identify prognostic
factors was limited to the non-HIV-infected group. Age,
sex, body mass index, underlying disease, the duration of
symptoms before admission, the pulmonary severity index
and hypoxemia at presentation, hypotension, and the
leukocyte, hemoglobin, and platelet counts were not
associated with mortality, ICU admission, or respiratory
failure during hospitalization (Table 2). However, a greater
degree of lymphopenia (593.0 vs. 1398.9 cells/ml, p < 0.05)
and shock during hospitalization (92% vs. 25%, p Z 0.004)
were associated with mortality.
Discussion
This retrospective study showed that the clinical charac-
teristics, treatment, and outcomes of PJP differ signifi-
cantly among the patients with and without HIV infection.
The mortality rates of HIV-infected and non-HIV-infectedpatients in the present study were similar to those of
published studies.3,16 Previous studies have noted that PJP
can be more fulminant among immunosuppressed non-HIV-
infected patients than among HIV-infected patients,8,17
resulting in a mortality rate as high as 50% in non-HIV-
infected patients with PJP.3,8,18 In our study, the duration
between admission and the initialization of PJP treatment
was longer in the non-HIV-infected group. Such a delay in
treatment is likely to be related to the delay in the diag-
nosis of PJP, for which the clinical manifestations and
radiologic abnormalities are nonspecific to make it difficult
to differentiate PJP from other opportunistic pulmonary
infections. Most importantly, the diagnostic yield of stain-
ing methods for respiratory samples for P. jiroveci is
limited,19 leading to an underestimation of the prevalence
of PJP in the at-risk population.
The prognosis of HIV-infected individuals with PJP has not
changed much despite major advances in caring for HIV-
infected patients during the past quarter of a century.20 By
contrast, the high mortality rate of non-HIV-infected
patients with PJP should prompt continued efforts to
improve their outcomes. The importance of early treatment
of non-HIV-infected patients with PJPhas not be emphasized
until recently.13,21 Our study also demonstrated that a delay
in anti-PJP treatment was more common among non-HIV-
infected patients. Physicians should be alert for the possi-
bility of PJP in immunocompromised patients with respira-
tory complaints and radiologic pulmonary infiltration.
In accordance with earlier studies,3,22 the clinical
symptoms of the HIV-infected and non-HIV-infected
patients with PJP were similar and nonspecific. In addi-
tion, these two populations have been shown to share
common findings for chest films or computed tomog-
raphy,22,23 although some differences in computed tomog-
raphy images have been reported.22 However, the similar
clinical presentations of PJP did not lead to early therapy in
the non-HIV-infected patients. In general, the HIV-infected
patients often received early antimicrobial therapy for PJP
and had a favorable outcome. However, the non-HIV-
infected patients were usually treated with appropriate
antimicrobial therapy starting, on average, 10 days after
admission and had complicated courses. One of the possible
reasons for this discrepancy may be related to the variation
in clinical alertness for PJP among attending physicians.
The HIV-infected patients were predominantly cared for by
infectious disease specialists, and most of the non-HIV-
infected patients were cared for by medical professionals
other than infectious disease specialists.
The standard therapy for PJP is co-trimoxazole at a dose
of trimethoprim 5e20 mg/kg/day. Nevertheless, only
a limited proportion of patients can complete the recom-
mended treatment course, usually 21 days, without expe-
riencing adverse events.24 We found that the treatment
regimen had been changed for almost one-half of patients
due to the adverse events of co-trimoxazole such as skin
rash or bone marrow suppression.
Owing to the lack of a reliable culture system of P. jir-
oveci, the diagnosis traditionally relied on conventional
staining, but this method is limited by a low sensitivity.19
The development of PCR-based diagnostic assays
improved the sensitivity to between 87 and 100%.19,25 The
negative predictive rate can be as high as 100%.19,25 Thus,
Table 2 Univariate analysis of risk factors associated with crude mortality in 20 non-HIV-infected patients with Pneumocystis
jiroveci pneumonia
Variables Patients, N (%) p
Survived (n Z 8) Fatal (n Z 12)
Female 5 (63) 6 (50) 0.67
Age, y (mean  SD) 53.6  15.1 47.9  17.2 0.46
Body mass index, kg/m2 (mean  SD) 23.2  3.3 21.3  1.1 0.26
Underlying diseases
Prior pulmonary disease 1 (13) 3 (25) 0.62
Chronic kidney disease 1 (13) 2 (17) 1.00
Diabetes mellitus 1 (13) 0 (0) 0.40
Hypertension 5 (63) 3 (25) 0.17
Cardiovascular disease 0 (0) 3 (25) 0.24
Hematologic malignancy 1 (13) 4 (33) 0.60
Solid cancer 1 (13) 2 (17) 1.00
Autoimmune disease 4 (50) 4 (33) 0.65
Recipient of a kidney transplant 2 (25) 0 (0) 0.15
Symptom onset before admission, da 3.3  5.2 8.9  18.2 0.48
Severity of illness at presentation
Pneumonia severity index 95.1  37.9 102.3  33.5 0.66
Hypoxemiab 4 (50) 9 (75) 0.36
Hypotension 1 (13) 3 (25) 0.62
Concurrent respiratory tract infection 1 (13) 1 (8) 1.00
Laboratory findings (mean  SD)
White blood cell count, cells/ml 11,262.5  5449.8 7608.3  4161.6 0.11
Hemoglobin, g/dl 11.1  2.4 11.3  2.3 0.81
Platelets, cells  103/ml 202.6  119.0 205.8  140.5 0.96
Lymphocytes, cells/ml 1398.9  1026.5 593.0  675.4 <0.05
Treatment and outcomes
Initiation of treatment after admission, da 8.8  7.2 11.1  12.0 0.68
Admission to intensive care unit 7 (88) 11 (92) 1.00
Respiratory failure 6 (75) 12 (100) 0.15
Shock during hospitalization 2 (25) 11 (92) 0.004
Pneumothorax 1 (13) 1 (8) 1.00
a Four non-HIV-infected patients with hospital-onset Pneumocystis jiroveci pneumonia were excluded.
b Oxyhemoglobin saturation by pulse oximetry <95% in room air or the need for oxygen.
Note: Prior pulmonary disease denotes a history of physician-diagnosed nonmalignant pulmonary disorder; cardiovascular disease:
coronary artery disease or stroke.
HIV Z human immunodeficiency virus; SD Z standard deviation.
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toxic empirical antimicrobial therapy for PJP.19 Therefore,
PCR-based assays are useful tools to guide the clinical
management of patients with suspected PJP.
In HIV-infected patients with PJP, a low lymphocyte
percentage ( 10%) has been identified as a predictor of
mortality.26 In our analysis of non-HIV-infected patients
with PJP, lymphopenia and shock during hospitalization
were associated with mortality. The association of the
lymphocyte count with the mortality rate of PJP in non-HIV-
infected individuals is parallel to a previous study.27
This study has several limitations. First, the clinical data
were collected retrospectively. Some factors that may
influence the outcome of PJP may be not available, such as
the serum levels of lactate dehydrogenase, C-reactive
protein,18 and albumin.28 In addition, not all patients in the
non-HIV-infected group received an HIV screening test.
Second, positive results in the nested PCR were not
confirmed by other tests, such as conventional staining. Inaddition, these positive results can be argued to represent
airway colonization rather than true infection with P. jir-
oveci.29,30 However, all of our patients had clinical symp-
toms and radiologic abnormalities compatible with true
infection. Therefore, the possibility of P. jiroveci coloni-
zation is minimal. In addition, the non-HIV-infected
patients with PJP had fewer fungal cells in the clinical
samples than the HIV-infected patients.31 Thus, the PCR-
based studies would be more sensitive to diagnose PJP for
the non-HIV-infected patients. Last, the number of patients
was relatively small, especially for analyzing the associa-
tion between clinical characters and mortality. Thus, the
clinical implications of our findings cannot be generally
applied to other patient populations. Some factors, such
the pneumonia severity index or the delayed treatment of
PJP, may have reached statistical significance if more
patients had been included in the present study.
In conclusion, among non-HIV-infected patients, even
under modern medical care, a delay in the initiation of
Pneumonia in immunocompromised patients 47antimicrobial therapy for PJP was common, and this delay
was associated with a worse outcome than that in the HIV-
infected population. Rapid and sensitive diagnostic assays
to confirm or rule out PJP are urgently needed to improve
the clinical outcomes of patients with PJP and to prevent
unnecessary exposure to co-trimoxazole in immunocom-
promised individuals.
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